Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Publication year range
1.
Pharm Dev Technol ; 20(3): 306-13, 2015 May.
Article in English | MEDLINE | ID: mdl-24417644

ABSTRACT

CONTEXT: Drug polymorphism could affect drug product dissolution, manufacturability, stability and bioavailability/bioequivalence. The impact of polymorphism on the manufacturability and in vitro dissolution profiles of sulindac capsules has not been studied yet. OBJECTIVE: To evaluate the impact of polymorphism on the manufacturability and in vitro dissolution of sulindac hard gelatin capsules. MATERIALS AND METHODS: Sulindac crystal forms I and II (SLDI and SLDII, respectively) were prepared and characterized. Powder formulations containing one of the polymorphs, lactose and magnesium stearate (at three different levels) were prepared and their flow properties determined. Hard gelatin capsules were filled with the formulations and tested for fill-weight variations. Drug dissolution for SLDI- and SLDII-containing hard gelatin capsules was determined. RESULTS: Differences in flow properties for each polymorph were observed, as well as for their formulations, which in turn affected capsule weight homogeneity. Statistically significant differences in the rate and extent of drug release were observed between SLDI- and SLDII-containing capsules. DISCUSSION: Formulations containing SLDI showed a better manufacturability and a better dissolution profile than those with SLDII. CONCLUSION: Sulindac crystalline form I was the best candidate for hard gelatin capsule formulation because of its technological and in vitro dissolution properties.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemistry , Chemistry, Pharmaceutical/methods , Excipients/chemistry , Sulindac/chemistry , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Capsules , Crystallization , Drug Liberation , Gelatin , Lactose/chemistry , Powders , Solubility , Stearic Acids/chemistry , Sulindac/administration & dosage
3.
Rev. odontol. Univ. Säo Paulo ; 2(2): 120-6, abr.-jun. 1988. tab
Article in Portuguese | LILACS, BBO - Dentistry | ID: lil-80413

ABSTRACT

Neste trabalho procurou-se avaliar os efeitos dos antiinflamatórios näo esteróides: Indometacina (indocid), Butazona (Fenilbutazona), Clinoril (Sulindac), Naprosin (Naproxen), Benflogin (Cloridrato de Benzidamina) e Inflaril (Acido neflúmico) nos leucogramas de ratos portadores de um processo inflamatório crônico provocado pela introduçäo intradérmica de lamínulas de vidro nos períodos de 3, 12 e 18 dias. O sangue para a contagem total dos leucócitos, eletrônica e diferencial, esfregaço, foi obtido por punçäo intracardíaca (Burhoe). A Indometacina, o Clinoril e a Butazona indicaram diminuiçäo de linfócitos e eosinófilos e aumento de monócitos e neutrófilos em todos os períodos e observaçäo em todos os períodos; o Inflaril reduziu o número de linfócitos, neutrofilia e eosinopenia em todos os períodos; o Inflaril reduziu o número de linfócitos e eosinófilos de aumentou os monócitos, com exceçäo de 3§ período, e os neutrófilos nos três períodos; e o Benflogin elevou os linfócitos na 1ª e 3ª fases, e os monócitos nos três períodos, e reduziu os neutrófilos nos dois primeiros, e os eosinfófilos nos dois últimos períodos. Todas as drogas usadas provocaram reduçäo de leucócitos em todos os períodos de tratamento, exceçäo feita ao Naprosin no 3§, ao Benflogin no 2§ e ao Inflaril no 1§ e 2§ períodos


Subject(s)
Rats , Animals , Anti-Inflammatory Agents, Non-Steroidal/blood , Benzydamine/administration & dosage , Benzydamine/blood , Phenylbutazone/administration & dosage , Phenylbutazone/blood , Sulindac/administration & dosage , Sulindac/blood , Indomethacin/administration & dosage , Indomethacin/blood , Naproxen/administration & dosage , Naproxen/blood , Niflumic Acid/administration & dosage , Niflumic Acid/blood
4.
Invest. med. int ; 12(4): 234-40, feb 1986. ilus
Article in Spanish | LILACS | ID: lil-46860

ABSTRACT

Mediante estudio doble ciego, se comparó el efecto sintomático de carprofeno y sulindac en pacientes con osteoartrosis de cadera, rodilla o ambas. Se analizan los resultados obtenidos para todos los síntomas relacionados con el proceso articular degenerativo: dolor en todas sus formas de manifestación y rigidez articular subjetiva; se hizo el registro con escalas de intensidad y escala visual analógica. Se consideraron también las opiniones globales del investigador y los pacientes así como la aparición de efectos indeseables. Se concluye que el efecto sintomático de carprofeno y sulindac es semejante aun cuando la analgesia total fue un suceso más común con el primero. La tolerancia fue muy superior en el grupo tratado con carprofeno registrándose efectos indeseables con una frecuencia tres veces mayor con sulindac que con carprofeno


Subject(s)
Middle Aged , Male , Female , Carbazoles/therapeutic use , Osteoarthritis/drug therapy , Sulindac/therapeutic use , Carbazoles/administration & dosage , Chemistry , Clinical Trials as Topic , Double-Blind Method , Sulindac/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL